Status | Study |
Withdrawn |
Study Name: Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2013-07-16 Interventions: Drug: AMG 386 Patients will re |
Completed |
Study Name: Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Condition: Transitional Cell Carcinoma Date: 2012-08-13 Interventions: Drug: Cabazitaxel 25 mg/m2, IV |
Completed |
Study Name: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2012-05-23 Interventions: Drug: Valrubicin Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days |
Completed |
Study Name: Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Condition: Urothelial Carcinoma Date: 2011-08-31 Interventions: Drug: Cabazitaxel |
Active, not recruiting |
Study Name: DNA Methylation and Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2011-06-20 |
Recruiting |
Study Name: DNA Methylation and Arsenic-associated Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2011-05-24 |
Completed |
Study Name: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2011-05-04 Interventions: Biological: DN24-02 DN24-02 is |
Recruiting |
Study Name: Tesetaxel for Previously Treated Patients With Bladder Cancer Condition: Carcinoma, Transitional Cell Date: 2010-10-05 Interventions: Drug: Tesetaxel Tesetaxel capsules orally once every 21 da |
Completed |
Study Name: The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma Condition: Carcinoma, Transitional Cell Date: 2010-08-25 |
Withdrawn |
Study Name: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2010-02-18 Interventions: Drug: Docetaxel Docetaxel IV 7 |